Innate and adaptive genetic pathways in HCV infection
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
Infection with hepatitis C virus (HCV) leads to a wide spectrum of clinical manifestations. This heterogeneity is underpinned by the host immune response and the genetic factors that govern it. Polymorphisms affecting both the innate and adaptive immunity determine the outcome of exposure. However the innate immune system appears to play a greater role in determining treatment-associated responses. Overall the effects of IFNL3/4 appear dominant over other polymorphic genes. Understanding how host genetics determines the disease phenotype has not been as intensively studied. This review summarizes our current understanding of innate and adaptive immunogenetic factors in the outcome of HCV infection. It focuses on how they relate to resolution and the progression of HCV-related liver disease, in the context of current and future treatment regimes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:85 |
|---|---|
| Enthalten in: |
Tissue antigens - 85(2015), 4 vom: 19. Apr., Seite 231-40 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Buchanan, R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.05.2016 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/tan.12540 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM246491299 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM246491299 | ||
| 003 | DE-627 | ||
| 005 | 20231227125123.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/tan.12540 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1223.xml |
| 035 | |a (DE-627)NLM246491299 | ||
| 035 | |a (NLM)25708172 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Buchanan, R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Innate and adaptive genetic pathways in HCV infection |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.05.2016 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a Infection with hepatitis C virus (HCV) leads to a wide spectrum of clinical manifestations. This heterogeneity is underpinned by the host immune response and the genetic factors that govern it. Polymorphisms affecting both the innate and adaptive immunity determine the outcome of exposure. However the innate immune system appears to play a greater role in determining treatment-associated responses. Overall the effects of IFNL3/4 appear dominant over other polymorphic genes. Understanding how host genetics determines the disease phenotype has not been as intensively studied. This review summarizes our current understanding of innate and adaptive immunogenetic factors in the outcome of HCV infection. It focuses on how they relate to resolution and the progression of HCV-related liver disease, in the context of current and future treatment regimes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a hepatitis C | |
| 650 | 4 | |a immunity, adaptive | |
| 650 | 4 | |a immunity, innate | |
| 650 | 4 | |a interferon | |
| 650 | 4 | |a interleukins | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a interferon-lambda, human |2 NLM | |
| 650 | 7 | |a IFNL4 protein, human |2 NLM | |
| 650 | 7 | |a Interleukins |2 NLM | |
| 650 | 7 | |a Interferons |2 NLM | |
| 650 | 7 | |a 9008-11-1 |2 NLM | |
| 700 | 1 | |a Hydes, T |e verfasserin |4 aut | |
| 700 | 1 | |a Khakoo, S I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tissue antigens |d 1971 |g 85(2015), 4 vom: 19. Apr., Seite 231-40 |w (DE-627)NLM00009482X |x 1399-0039 |7 nnns |
| 773 | 1 | 8 | |g volume:85 |g year:2015 |g number:4 |g day:19 |g month:04 |g pages:231-40 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/tan.12540 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 85 |j 2015 |e 4 |b 19 |c 04 |h 231-40 | ||